Neurology
Gilgamesh completes SAD and MAD studies of MDD therapy
The company plans to commence a Phase IIa study in MDD patients in the second half of this year.
Imcyse concludes enrolment in Phase I portion of RRMS therapy trial
Major unmet needs plague classification and treatment of myasthenia gravis patients
AnHeart doses first patient in glioma therapy trial
Alzheimer’s Disease: Some trials to watch over the next year
Alzamend targets Phase IIa trial for bipolar treatment candidate
